Navigation Links
Novel LABA/LAMA Products Will Capture Greater Market Share than the LABA/ICS or LAMA Drug Classes by 2022
Date:8/28/2013

BURLINGTON, Mass., Aug. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of a new drug class that will drive sales through 2022. Currently, the COPD market is dominated by Boehringer Ingelheim/Pfizer's long-acting muscarinic antagonist (LAMA) Spiriva and GlaxoSmithKline's long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) Advair/Seretide/Adoair. In 2012, total sales of these two market leaders constituted nearly two-thirds of COPD sales. However, following the launch of new agents, particularly those that offer advantages in dosing, their combined market share will diminish to less than 15 percent in 2022.

The Pharmacor advisory service entitled Chronic Obstructive Pulmonary Disease finds that the market for COPD will increase from nearly $10 billion in 2012 to $14 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Five fixed-dose combination inhalers comprised of a LABA and a LAMA are forecasted to launch over the next ten years and this new drug class will collectively garner over 35 percent market share in 2022. Among these novel combinations, GlaxoSmithKline/Theravance's Anoro and Boehringer Ingelheim's olodaterol/tiotropium are expected to experience the greatest success, totaling nearly $4 billion in major-market sales in 2022.

"The clinical trial data for LABA/LAMAs continue to be promising and these combination products will provide the convenience of delivering the two major bronchodilator classes that are recommended as first-line maintenance options in treatment guidelines," said Decision Resources Senior Director Joanna Kim, M.Ed.

The findings also reveal that GlaxoSmithKline/Theravance's Breo/Relvar will perform strongly and act as another key growth driver, alongside the LABA/LAMAs, in the COPD market. Breo/Relvar's once-daily administration will be the first to offer dosing improvement over Advair which, together with efficacy that is comparable to Advair, will challenge Advair's dominance in all major markets.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
2. Novel Use of Pressure BioSciences Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design
3. Lakewood-Amedex Announces Its Novel Bisphosphocin Class Of Antimicrobials Are Active Against NDM-1 Positive Bacterial Strains
4. Naurex Announces Issuance Of New Patent For Novel Antidepressant GLYX-13
5. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
6. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
7. NextDocs and Novella to Present on eTMF at DIA 2013
8. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
9. Adult and Adolescent Vaccines Market to 2018 Report - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
10. Quantum Materials Tetrapod Quantum Dots Break Kashas Rule: Enhanced Performance Enables Commercialization of Novel Discovery
11. ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CLEVELAND , Jan. 19, 2017 ViewRay, ... (DFG), a federal institution supporting research in ... installation and patient treatments at the University Clinic Heidelberg ... The MRIdian Linac program will be headed ... who also heads radiation oncology at the German Cancer ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017   Science ... is excited to announce that the first five ... Biology  (RP:CB) have been published in eLife today. ... project represents the first practical evaluation of reproducibility ... in reproducible studies. Unlike other assessments of reproducibility, ...
(Date:1/19/2017)... -- New Review of Safinamide - ... and Motor Complications in Mid- to Late-stage Parkinson,s ... ... C Warren Olanow , ... 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published recently ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Bill Howe Plumbing, Heating ... the American Heart Association; “Howe” Healthy is Your Heart Drawing Contest The ... active. Each year, Bill Howe Plumbing, Heating & Air receives over 600 entries. The ...
(Date:1/19/2017)... Marriottsville, MD (PRWEB) , ... January 19, 2017 , ... ... launched six new clients into the US market. , Over the past 20 years ... the past 4 weeks SFI has launched six new clients into the US market. ...
(Date:1/19/2017)... Georgia (PRWEB) , ... January 19, 2017 , ... ... Surgeons hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons ... advancements in breast surgery. Covering topics from cosmetic breast augmentation to ...
(Date:1/18/2017)... ... 2017 , ... A recent video posting of a new fidget product gathered ... fidgeting to relieve stress and anxiety. No one was more surprised than Think ... just completed a successful Kickstarter campaign raising $67,000 on the popular crowdfunding platform. ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... manage it from the number one doctor-recommended OTC antiperspirant, Certain Dri. , Excessive ... go untreated. , Certain Dri created this infographic to explain the seven types ...
Breaking Medicine News(10 mins):